Ergotamine-associated valvulopathy with recurrent chylous pleural effusion

We report a rare case of ergotamine-associated mitral stenosis in a 55-year-old woman who presented with recurrent chylous pleural effusion. Echocardiographic, gross, and microscopic features of the mitral valve were consistent with chronic ergotamine-induced valvulopathy. We conclude that medicatio...

Full description

Saved in:
Bibliographic Details
Published in:Texas Heart Institute journal 2012-01, Vol.39 (5), p.736-738
Main Authors: Bois, John P, Ponnada, Vara Venkata, O'Cochlain, D Fearghas, Brady, Peter A, Edwards, William D, Klarich, Kyle W
Format: Article
Language:English
Subjects:
Case Reports
Chylothorax - chemically induced
Chylothorax - diagnosis
Dopamine Agonists - adverse effects
Echocardiography, Doppler, Color
Echocardiography, Transesophageal
Ergotamine - adverse effects
Female
Heart Valve Prosthesis Implantation
Humans
Middle Aged
Mitral Valve Stenosis - chemically induced
Mitral Valve Stenosis - diagnosis
Mitral Valve Stenosis - surgery
Pleural Effusion - chemically induced
Pleural Effusion - diagnosis
Predictive Value of Tests
Recurrence
Treatment Outcome
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We report a rare case of ergotamine-associated mitral stenosis in a 55-year-old woman who presented with recurrent chylous pleural effusion. Echocardiographic, gross, and microscopic features of the mitral valve were consistent with chronic ergotamine-induced valvulopathy. We conclude that medication-induced valvulopathy should be included in the differential diagnosis of valvular heart disease. In addition, cardiac function should be monitored before and during long-term therapy with ergotamine or ergotamine-derived dopamine agonists.
ISSN:0730-2347
1526-6702